American Society for Microbiology, Microbiology Spectrum, 2(10), 2022
DOI: 10.1128/spectrum.01480-21
Full text: Download
The validity of HPV ctDNA as a marker of HPV-driven cancers has been previously reported. Herein we validated an alternative to ddPCR for HPV16 ctDNA detection, using a bead-based HPV genotyping assay that offers the potential advantage of reducing the cost of clinical management due to the multiplex capability of the test, thus facilitating its use in clinical settings.